Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy (PERSEUS-IT)

Bayer

Status: Completed

Conditions: Wet Macular Degeneration

Treatments: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Study type: Observational

Funder types: Industry

Identifiers

NCT02289924

17634

EY1415IT (Other Identifier)

Details and patient eligibility

About

The main objectives of this non-interventional cohort field study are to evaluate effectiveness of Eylea and to describe follow-up as well as treatment patterns in patients with wAMD (wet age-related macular degeneration) in routine clinical practice in Italy for a study population of "naïve" patients

Enrollment: 912 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• "Naïve" patients with wet AMD(age-related macular degeneration) treated with Eylea (in accordance with the local Summary of Product Characteristics, SPC).

Exclusion criteria

• Exclusion criteria as listed in the local SPC. Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.
• Any concomitant therapy with another agent to treat wet AMD in the study eye.
• Any prior or concomitant therapy with another drug for wAMD.

Trial design

912 participants in 1 patient group

Cohort 1

Description:

According to the recommendations of the Summary of Product Characteristics (SmPC) in Italy

Treatment:

Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)